Meeting
2016 ASCO Annual Meeting
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
Authors
Francois M. Lebel
ZIOPHARM Oncology, Boston, MA
Francois M. Lebel , John A. Barrett , E. Antonio Chiocca , John Yu , Rimas Vincas Lukas , Seema Nagpal , Priya Kumthekar , Suma Krishnan , Laurence JN Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02026271
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2052)
DOI
10.1200/JCO.2016.34.15_suppl.2052
Abstract #
2052
Poster Bd #
239
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca
Poster
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca
Poster
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.
First Author: Rimas Vincas Lukas
Poster
2023 ASCO Annual Meeting
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
First Author: Mason Webb